Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Sponsor: The University of Texas Medical Branch, Galveston
Summary
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Official title: Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age
Key Details
Gender
FEMALE
Age Range
27 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
618
Start Date
2023-01-18
Completion Date
2027-08
Last Updated
2025-10-06
Healthy Volunteers
Yes
Interventions
9-valent HPV vaccine, 2 doses alternate timing
Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
9-valent HPV vaccine, 3 doses standard timing
This will be the comparison group for the 2-dose group.
Locations (1)
University of Texas Medical Branch
Galveston, Texas, United States